Clinical trial

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

NCT05895643

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Semaglutide Injectable Product Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-06-13

PhasePHASE2

Conditions

Alcohol Abuseverified · MONDO: alcohol abuse

Alcohol Addictionunresolved

Alcohol Dependenceverified · MONDO: alcohol dependence

Alcohol Use Disorderunresolved

Interventions

Semaglutide Injectable ProductDRUG

PlaceboDRUG

Sponsors & collaborators

Psychiatric Centre Rigshospitaletlead sponsor

Neurobiology Research Unitcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05895643 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.